Evidence map›Paper›PMID 31333222›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

Treatment Effect of Tuftsin and Antigen Peptide Combined with Immune Cells on Colorectal Cancer.

Boyuan Zou, Shaoyou Xia, Xiaohui Du, Yingxin Xu, Ning Ning, Songyan Li, Da Teng, Hao Li, Zilong Hu, Shidong Hu and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Boyuan ZouDepartment of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, China (mainland).
Shaoyou XiaDepartment of General Surgery, The General Hospital of People's Liberation Army, Beijing, China (mainland).
Xiaohui DuDepartment of General Surgery, The General Hospital of People's Liberation Army, Beijing, China (mainland).
Yingxin XuDepartment of General Surgery, The General Hospital of People's Liberation Army, Beijing, China (mainland).
Ning NingDepartment of General Surgery, The General Hospital of People's Liberation Army, Beijing, China (mainland).
Songyan LiDepartment of General Surgery, The General Hospital of People's Liberation Army, Beijing, China (mainland).
Da TengDepartment of General Surgery, The General Hospital of People's Liberation Army, Beijing, China (mainland).
Hao LiDepartment of General Surgery, The General Hospital of People's Liberation Army, Beijing, China (mainland).
Zilong HuDepartment of General Surgery, The General Hospital of People's Liberation Army, Beijing, China (mainland).
Shidong HuDepartment of General Surgery, The General Hospital of People's Liberation Army, Beijing, China (mainland).
Yufeng WangDepartment of General Surgery, The General Hospital of People's Liberation Army, Beijing, China (mainland).
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND The aim of this study was to investigate the effect of antigenic peptides on dendritic cell maturation and activation as well as the role of dendritic cell induced cell function. The tumor-specific cytotoxic T lymphocytes induced by activation of the dendritic cells were also evaluated. MATERIAL AND METHODS SW-480 cell lysate and peptide antigens were selected as adjuvants in dendritic cell sensitization, and tuftsin was used to induce the phagocytosis of dendritic cells. Immature dendritic cells were stimulated with the antigen and adjuvant as follows: group A was negative control; group B was SW-480 (20 μg/mL); group C was SW-480 (20 μg/mL)+tumor necrosis factor (TNF)-alpha (10 μg/mL); group D was SW-480 (20 μg/mL)+tuftsin (20 μg/mL); group E was antigen peptide (2 μg/mL); group F was antigen peptide (2 μg/mL)+TNF-alpha (10 μg/mL); group G was antigen peptide (2 μg/mL)+tuftsin (20 μg/mL). Cytotoxic T lymphocytes activation and in vitro anti-tumor effects were examined by detecting the maturation marks of dendritic cells as well as interleukin (IL)-10 and IL-12 levels secreted by dendritic cells. Cells with the strongest immunizing effects were injected into nude mice and tumor suppression status was evaluated. RESULTS Group D (SW-480+tuftsin), group E (antigen peptides), group F (antigen peptide+TNF-alpha), and group G (antigen peptides+tuftsin) displayed significant differences compared to the control group (P<0.05). Group G (antigen peptides+tuftsin) could also promote the secretion of cytokines IL-12, as well as inhibit cytokine IL-10 secretion, compared to the other experimental groups (P<0.05). In the in vivo experiments of tumor inhibitions, antigenic polypeptide+tuftsin was the most effective (P<0.05). CONCLUSIONS Combination of cytotoxic T lymphocytes and T peptide therapy in treating human colorectal cancer might be used as a new treatment strategy based on adoptive cellular immunotherapy.

Indexed as

AnimalsCell Line, TumorColonic NeoplasmsColorectal NeoplasmsDendritic CellsHumansImmunotherapy, AdoptiveLymphocyte ActivationMiceMice, NudePeptidesT-Lymphocytes, CytotoxicTuftsinTumor Necrosis Factor-alphaPeptidesTuftsinTumor Necrosis Factor-alpha

Identifiers

PMID31333222
PMCPMC6668490
OpenAlexW2964321870

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.